In clinical trials, people adding BENLYSTA to their treatment plan decreased their risk of severe flares in the first year of use. Results may vary. ‡Compared to other lupus medications alone.§A reduction of steroid dose was seen but was not statistically significant. ...
See lupus nephritis data ‡ SRI-4 response rate at Week 52 (primary endpoint). BLISS-LN = Belimumab International Study in Lupus Nephritis; CI = confidence interval; CRR = complete renal response; OR = odds ratio.. BENLYSTA is recommended by EULAR and KDIGO as a treatment option for lupus...
参考文献: GSK receives approval for Benlysta in Japan for the treatment of systemic lupus erythematosus (us.gsk.com/en-us/media/ gsk-receives-approval -for-benlysta-in-japan-for-the-treatment-of-systemic-lupus-erythematosus/)发布于 2017-10-10 20:19 ...
BENLYSTA is the first and only FDA-approved treatment for both lupus and lupus nephritis. It’s available for adults in 2 administration options—subcutaneous (SC) injectionorintravenous (IV) infusion. For children ages 5 and above with active lupus or lupus nephritis, BENLYSTA is available as ...
SC剂型于2017年获得美国FDA批准,产品有2种形式:单剂量预灌封注射器和单剂量自动注射器,患者通过培训后可自行皮下注射给药,该剂型将为SLE患者群体提供一种重要的治疗选择。 原文出处:Intravenous Benlysta is the first biologic treatment ...
Benlysta's mechanism of action involves targeting and blocking a protein called B-lymphocyte stimulator (BLyS) that usually helps B cells survive and produce antibodies. In lupus, B cells are overactive and these produce harmful autoantibodies that attack healthy tissue. By blocking BLyS, Benlysta ...
"The wait is over, and the lupus community can now rejoice over today's historic approval, which marks a major milestone in lupus research and treatment," said Richard Furie, MD, chief of the division of rheumatology and allergy-clinical rheumatology atNorth Shore-LIJ Health Systemin New York...
SC剂型于2017年获得美国FDA批准,产品有2种形式:单剂量预灌封注射器和单剂量自动注射器,患者通过培训后可自行皮下注射给药,该剂型将为SLE患者群体提供一种重要的治疗选择。(生物谷Bioon.com) 原文出处:Intravenous Benlysta is the first biologic treatment to be approved for children with lupus in Europe...
BENLYSTA.The article offers brief information on the monoclonal antibody drug Benlysta, which is indicated for the treatment of systemic lupus erythematosus in adults, from Human Genome Sciences Inc. and GlaxoSmithKline.EBSCO_AspMPR - Residents' Edition...
BENLYSTA (belimumab) is indicated for the treatment of: patients 5 years of age and older with activesystemic lupus erythematosus(SLE) who are receiving standard therapy, and patients 5 years of age and older with activelupusnephritiswho are receiving standard therapy. ...